Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.
Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population.
复制标题
DOI：
10.1002/acr.21638
复制
发表时间：
2012-07
影响因子：
4.7
通讯作者：
Delzell, Elizabeth
中科院分区：
文献类型：
--
作者：
Curtis, Jeffrey R.;Yun, Huifeng;Matthews, Robert;Saag, Kenneth G.;Delzell, Elizabeth
我们的目的是评估美国医疗保险登记者中唑来膦酸盐和IV伊班膦酸盐新用户的依从性。我们使用来自医疗保险5%随机样本的数据来评估连续A+B部分按服务收费覆盖的IV唑来膦酸盐和IV伊班膦酸盐的新用户。结果是依从性，通过覆盖天数比例（PDC）进行量化，并连续和二分测量（>= 80%）。所有患者的随访时间从18-27个月延长。与唑来膦酸盐依从性低相关的因素采用逻辑回归进行评估。我们确定了775名唑来膦酸盐新用户和846名IV伊班膦酸盐新用户。对于这两种药物，30-48%的首次输注是在门诊输液中心进行的，而不是在医生办公室进行的。唑来膦酸盐使用者的平均PDC为82%，大于IV伊班膦酸盐使用者的平均PDC（58- 62%，取决于时间段，p < 0.0001）。大约30%的唑来膦酸使用者没有接受第二次输注。与唑来膦酸依从性低相关的因素包括年龄较大和在门诊输液中心而不是在医生办公室接受首次输液。较低剂量的IV双膦酸盐并没有解决骨质疏松症处方药物依从性不佳的问题。继续保证干预措施，以提高长期坚持骨质疏松症治疗。
Our objective was to evaluate adherence among new users of zoledronate and IV ibandronate among U.S. Medicare enrollees. We used data from the Medicare 5% random sample to evaluate new users of IV zoledronate and IV ibandronate with continuous Part A+B fee-for-service coverage. The outcome was adherence as quantified by the proportion of days covered (PDC), measured continuously and dichotomously (>= 80%). Follow-up time extended from 18–27 months for all individuals. Factors associated with low adherence with zoledronate were evaluated with logistic regression. We identified 775 new users of zoledronate and 846 new users of IV ibandronate. For both drugs, 30–48% of first infusions were given in an outpatient infusion center, not in a physician office. The mean PDC for zoledronate users was 82%, which was greater than the mean PDC for the IV Ibandronate users (58–62%, depending on time period, p < 0.0001). Approximately 30% of zoledronate users did not receive a second infusion. Factors associated with low adherence to zolendronate included older age and receipt of the first infusion in an outpatient infusion center rather than a physician’s office. Less frequently dosed IV bisphosphonates have not resolved the problem of suboptimal adherence with prescription osteoporosis medications. Interventions continue to be warranted to improve long term adherence with osteoporosis treatments.
登录
查看更多内容
影响因子：
4
作者：
Solomon, D. H.;Gleeson, T.;Iversen, M.;Avorn, J.;Brookhart, M. A.;Lii, J.;Losina, E.;May, F.;Patrick, A.;Shrank, W. H.;Katz, J. N.
通讯作者：
Katz, J. N.
影响因子：
4
作者：
Rabenda, V.;Mertens, R.;Reginster, J. -Y.
通讯作者：
Reginster, J. -Y.
影响因子：
5.8
作者：
Delmas, Pierre D.;Vrijens, Bernard;Watts, Nelson B.
通讯作者：
Watts, Nelson B.
影响因子：
4
作者：
Gleeson, T.;Iversen, M. D.;Avorn, J.;Brookhart, A. M.;Katz, J. N.;Losina, E.;May, F.;Patrick, A. R.;Shrank, W. H.;Solomon, D. H.
通讯作者：
Solomon, D. H.
影响因子：
4
作者：
Sheehy, O.;Kindundu, C. M.;LeLorier, J.
通讯作者：
LeLorier, J.